Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Dami&Xiaomi | 2022 | Series D | $42.0M | Shenzhen |
| Achilles Therapeutics | 2022 | Grant | $4.1M | London |
| MiroBio | 2022 | Series B | $97.0M | Oxford |
| Frontera Therapeutics | 2022 | Series B | $160.0M | Bedford |
| Chinook Therapeutics | 2022 | Post Ipo Equity | $105.0M | Vancouver |
| Laekna Therapeutics | 2022 | Series D | $61.0M | Shanghai |
| Puma Biotechnology | 2022 | Post Ipo Equity | $10.0M | Los Angeles |
| MDClone | 2022 | Series C | $63.0M | Be'er Sheva |
| HanBio Therapeutics | 2022 | Series A | $40.0M | Shanghai |
| Gennao Bio | 2021 | Series A | $1.0M | New York |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 176 | Dami&Xiaomi | Series D | $42.0M | Shenzhen, China |
| 177 | Achilles Therapeutics | Grant | $4.1M | London, United Kingdom |
| 178 | MiroBio | Series B | $97.0M | Oxford, United Kingdom |
| 179 | Frontera Therapeutics | Series B | $160.0M | Bedford, United States |
| 180 | Chinook Therapeutics | Post Ipo Equity | $105.0M | Vancouver, Canada |
| 181 | Laekna Therapeutics | Series D | $61.0M | Shanghai, China |
| 182 | Puma Biotechnology | Post Ipo Equity | $10.0M | Los Angeles, United States |
| 183 | MDClone | Series C | $63.0M | Be'er Sheva, Israel |
| 184 | HanBio Therapeutics | Series A | $40.0M | Shanghai, China |
| 185 | Gennao Bio | Series A | $1.0M | New York, United States |
Dami&Xiaomi is a child autism intervention agency.
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
MiroBio is Harnessing the natural control mechanisms of the immune system.
Frontera Therapeutics is an AAV gene therapy company that focuses on rAAV therapies for the global market.
Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science.
Laekna Therapeutics is a biotech company focusing on drug discovery and development.
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
MDClone offers a powerful, self-service data analytics environment enabling healthcare collaboration, research, and innovation.
HanBio Therapeutics is a biotechnology company committed to researching and developing next generation transformative medicines.
Gennao Bio is a genetic medicines company that develops targeted nucleic acid therapeutics to cure muscle diseases.
Emergence is a biopharmaceutical company working on novel ADC immunotherapies for cancers with a high unmet need.
Edge Medical Robotics is a surgical robot platform company focused on design, R&D, and commercialization of advance medical devices.
PierianDx is catalyzing global adoption of genomic sequencing in healthcare
Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.
A private biopharmaceutical company .
XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Zentera Therapeutics is a biopharmaceutical company.
Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.
Yuanxin Huibao is a health insurance technology service provider.
Zion Pharma is a drug discovery platform.
Turnstone Biologics is a privately-held clinical stage biotech company.
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform.
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.
OrbiMed has invested in 239 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
OrbiMed's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 24 different industry categories.
Among tracked funding rounds, Beijing Yuan Xin received $231.8M in a Series F round. OrbiMed's total known invested capital is $12.2B.
OrbiMed's average investment size is $87.5M across its portfolio of 239 companies.
Recent OrbiMed portfolio additions include Dami&Xiaomi, Achilles Therapeutics, MiroBio, Frontera Therapeutics, Chinook Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors